# Efficacy Study of Telbivudine in Chronic Hepatitis B Patients

> **NCT01958229** · — · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 23 (actual)

## Conditions studied

- Chronic Hepatitis B
- Roadmap Concept in Chronic Hepatitis B Treatment
- 24-week PCR Negativity of Telbivudine
- PCR Negativity at 52 and 104 Week
- HBeAg Seroconversion Rate at 52 and 104 Week

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01958229
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-03
- **Final completion:** 2013-04
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2013-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01958229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01958229, "Efficacy Study of Telbivudine in Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01958229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*